Nab-paclitaxel combined with oxaliplatin and S-1 as conversion therapy for advanced gastric adenocarcinoma.

被引：0
|
作者：
Ji, Ke
Bu, Zhaode
Yang, Heli
Wang, Zhenning
Liu, Funan
Liang, Pin
Dong, Yan
Zhang, Jie
Zhao, Qun
Liu, Yang
Ji, Jiafu
机构：
[1] Beijing Canc Hosp, Beijing, Peoples R China
[2] Peking Univ Canc Hosp, Minist Educ, Dept Gastrointestinal Surg, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China
[3] China Med Univ, Affiliated Hosp 1, Shenyang, Peoples R China
[4] First Hosp China Med Univ, Shenyang, Peoples R China
[5] Dalian Med Univ, Affiliated Hosp 1, Dalian, Peoples R China
[6] Fourth Hosp Hebei Med Univ, Shijiazhuang, Peoples R China
[7] Fourth Hosp Hebei Med Univ, Hebei Tumor Hosp, Shijiazhuang, Hebei, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
343
引用
收藏
页码：343 / 343
页数：1
相关论文
共 50 条
  • [41] The comparison of the usefulness of nab-paclitaxel and paclitaxel for advanced or recurrent gastric cancer
    Kimura, Yasue
    Kusumoto, Tetsuya
    Kusumoto, Eiji
    Sugiyama, Masahiko
    Ohta, Mitsuhiko
    Tsutsumi, Norifumi
    Sakaguchi, Yoshihisa
    Ikejiri, Koji
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [42] A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer
    Norisuke Nakayama
    Kenji Ishido
    Keisho Chin
    Ken Nishimura
    Mizutomo Azuma
    Satoshi Matsusaka
    Yasuhiro Inokuchi
    Satoshi Tanabe
    Yosuke Kumekawa
    Wasaburo Koizumi
    Gastric Cancer, 2017, 20 : 350 - 357
  • [43] Nab-paclitaxel plus S-1 as first line treatment for advanced or metastatic biliary tract adenocarcinoma: A phase 2 study.
    Sun, Yongkun
    Zhou, Ai-Ping
    Zhang, Wen
    Yang, Lin
    Cui, Chengxu
    Jiang, Zhichao
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [44] A study of relacorilant in combination with nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.
    Borazanci, Erkut Hasan
    Bahary, Nathan
    Oberstein, Paul Eliezer
    Chung, Vincent
    Skeel, Roland T.
    Chiorean, E. Gabriela
    Greenstein, Andrew E.
    Pashova, Hristina I.
    Tudor, Iulia Cristina
    Mann, Grace
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [45] Clinical study of nab-paclitaxel in combination with S-1 as first-line therapy in patients with advanced pancreatic cancer.
    Hu, Yi
    Sun, Danyang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [46] Intraperitoneal Paclitaxel Combined with S-1 Plus Oxaliplatin for Advanced Gastric Cancer with Peritoneal Metastasis: a Phase I Study
    Kim, Dong-Wook
    Seo, Won Jun
    Youn, Sang Il
    Jee, Ye Seob
    Jang, You-Jin
    Kim, Jong-Han
    JOURNAL OF GASTRIC CANCER, 2021, 21 (04) : 418 - 425
  • [47] The Role of nab-Paclitaxel Plus Gemcitabine Therapy for Recurrent Pancreatic Cancer Refractory to Gemcitabine and S-1
    Kagawa, S.
    Yoshitomi, H.
    Shimizu, H.
    Ohtsuka, M.
    Kato, A.
    Furukawa, K.
    Takayashiki, T.
    Takano, S.
    Kuboki, S.
    Suzuki, D.
    Sakai, N.
    Miyazaki, M.
    PANCREAS, 2015, 44 (08) : 1385 - 1385
  • [48] Concurrent docetaxel and S-1 compared with oxaliplatin and s-1 as first-line therapy for advanced gastric adenocarcinoma: A retrospective study.
    Tan, Siyi
    Xie, Jiaqi
    Wei, Jia
    Liu, Qin
    Du, Juan
    Liu, Baorui
    Yang, Yang
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [49] Feasibility of neoadjuvant S-1 and oxaliplatin followed by surgery for resectable advanced gastric adenocarcinoma
    Honma, Yoshitaka
    Yamada, Yasuhide
    Terazawa, Tetsuji
    Takashima, Atsuo
    Iwasa, Satoru
    Kato, Ken
    Hamaguchi, Tetsuya
    Shimada, Yasuhiro
    Ohashi, Masaki
    Morita, Shinji
    Fukagawa, Takeo
    Machida, Nozomu
    Katai, Hitoshi
    SURGERY TODAY, 2016, 46 (09) : 1076 - 1082
  • [50] Safety and Efficacy of Camrelizumab in Combination With Nab-Paclitaxel Plus S-1 for the Treatment of Gastric Cancer With Serosal Invasion
    Lin, Ju-Li
    Lin, Jian-Xian
    Lin, Jun Peng
    Zheng, Chao-Hui
    Li, Ping
    Xie, Jian-Wei
    Wang, Jia-bin
    Lu, Jun
    Chen, Qi-Yue
    Huang, Chang-Ming
    FRONTIERS IN IMMUNOLOGY, 2022, 12
12345